Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through bim overexpression: Implications for cancer treatment

Neoplasia (United States)

Volumn 15, Issue 1, 2013, Pages 49-60

  Savry, Amandine ^a   Carre, Manon ^a   Berges, Raphael ^a   Rovini, Amandine ^a   Pobel, Isabelle ^a   Chacon, Christine ^a   Braguer, Diane ^a   Bourgarel Rey, Véronique ^a  

^a University of the Mediterranean Aix Marseille II   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; DOXORUBICIN; NAVELBINE; PACLITAXEL; PROTEIN BCL 2; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; MICROARRAY ANALYSIS; MICROTUBULE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

EID: 84873037229     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121074     Document Type: Article

References (57)

1. Estève M-A, Carré M, and Braguer D (2007). Microtubules in apoptosis induction: are they necessary? Curr Cancer Drug Targets 7, 713-729.
2. Honore S, Pasquier E, and Braguer D (2005). Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 62, 3039-3056.
3. Rovini A, Carré M, Bordet T, Pruss RM, and Braguer D (2010). Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem Pharmacol 80, 884-894.
4. André N, Carré M, Brasseur G, Pourroy B, Kovacic H, Briand C, and Braguer D (2002). Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett 532, 256-260.
5. Akiyama T, Dass CR, and Choong PFM (2009). Bim-targeted cancer therapy: a link between drug action and underlyingmolecular changes. MolCancerTher 8, 3173-3180.
6. Youle RJ and Karbowski M (2005). Mitochondrial fission in apoptosis. Nat Rev Mol Cell Biol 6, 657-663.
7. Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, Kurth MJ, Shaw JT, Hinshaw JE, Green DR, et al. (2008). Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell 14, 193-204.
8. Smirnova E, Griparic L, Shurland DL, and Van der Bliek AM (2001). Dynaminrelated protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell 12, 2245-2256.
9. Sheridan C and Martin SJ (2010). Mitochondrial fission/fusion dynamics and apoptosis. Mitochondrion 10, 640-648.
10. Autret A and Martin SJ (2009). Emerging role for members of the Bcl-2 family in mitochondrial morphogenesis. Mol Cell 36, 355-363.
11. Cleland MM, Norris KL, Karbowski M, Wang C, Suen D-F, Jiao S, George NM, Luo X, Li Z, and Youle RJ (2011). Bcl-2 family interaction with the mitochondrial morphogenesis machinery. Cell Death Differ 18, 235-247.
12. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, Westra WH, Wada H, Busse PM, Ellisen LW, et al. (2009). Bcl-2 blocks cisplatininduced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 15, 1645-1654.
13. Sartorius UA and Krammer PH (2002). Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97, 584-592.
14. Tabuchi Y, Matsuoka J, Gunduz M, Imada T, Ono R, Ito M, Motoki T, Yamatsuji T, Shirakawa Y, Takaoka M, et al. (2009). Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol 34, 313-319.
15. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, ItriLM, et al. (2009). 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 27, 5208-5212.
16. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, and Vokes EE (2008). Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 26, 870-876.
17. Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, et al. (2009). Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 20, 1264-1269.
18. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, et al. (2008). Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14, 7909-7916.
19. Inoue Y, Gika M, Abiko T, Oyama T, Saitoh Y, Yamazaki H, Nakamura M, Abe Y, Kawamur M, and Kobayashi K (2005). Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol Rep 13, 259-264.
20. Del Bufalo D, Biroccio A, Trisciuoglio D, Bruno T, Floridi A, Aquino A, and Zupi G (2002). Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. Eur J Cancer 38, 2455-2462.
21. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO, and Scambia G (2003). Bcl-2 downregulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 64, 51-58.
22. Estève M-A, Carré M, Bourgarel-Rey V, Kruczynski A, Raspaglio G, Ferlini C, and Braguer D (2006). Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol Cancer Ther 5, 2824-2833.
23. Li R, Moudgil T, Ross HJ, and Hu H-M (2005). Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ 12, 292-303.
24. Khawaja NR, Carré M, Kovacic H, Estève MA, and Braguer D (2008). Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria. Mol Pharmacol 74, 1072-1083.
25. Kang MH and Reynolds CP (2009). Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15, 1126-1132.
26. Puthalakath H, Huang DC, O'Reilly LA, King SM, and Strasser A (1999). The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 3, 287-296.
27. Sunters A, Fernández de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC, and Lam EW (2003). FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxeltreated breast cancer cell lines. J Biol Chem 278, 49795-49805.
28. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, and Greenberg ME (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868.
29. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, and Greenberg ME (2001). Protein kinase SGK mediates survival signals by phosphorylating the Forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21, 952-965.
30. Zhang H, Yousem SA, Franklin WA, Elder E, Landreneau R, Ferson P, Keenan R, Whiteside T, and Levitt ML (1998). Differentiation and programmed cell deathrelated intermediate biomarkers for the development of non-small cell lung cancer: a pilot study. Hum Pathol 29, 965-971.
31. Del Bufalo D, Biroccio A, Leonetti C, and Zupi G (1997). Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J 11, 947-953.
32. Gao Q, Yang S, and Kang M-Q (2012). Influence of survivin and Bcl-2 expression on the biological behavior of non-small cell lung cancer. Mol Med Report 5, 1409-1414.
33. Clybouw C, Hadji A, ElMchichi B, Auffredou M-T, Leca G, and Vazquez A (2009). BimL upregulation induced by BCR cross-linking in BL41 Burkitt's lymphoma results from a splicing mechanism of the BimEL mRNA. Biochem Biophys Res Commun 383, 32-36.
34. Jordan MA, Toso RJ, Thrower D, and Wilson L (1993). Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90, 9552-9556.
35. Rose WC (1992). Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3, 311-321.
36. Fujimoto S (1994). Study for modifying activity of solvents on antitumor activity of paclitaxel. Gan To Kagaku Ryoho 21, 665-670.
37. Pasquier E, Carré M, Pourroy B, Camoin L, Rebaï O, Briand C, and Braguer D (2004). Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 3, 1301-1310.
38. André N, Braguer D, Brasseur G, Gonçalves A, Lemesle-Meunier D, Guise S, Jordan MA, and Briand C (2000). Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 60, 5349-5353.
39. Rovini A, Savry A, Braguer D, and Carré M (2011). Microtubule-targeted agents: when mitochondria become essential to chemotherapy. Biochim Biophys Acta 1807, 679-688.
40. Chun E and Lee K-Y (2004). Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 315, 771-779.
41. Koty PP, Zhang H, Franklin WA, Yousem SA, Landreneau R, and Levitt ML (2002). In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions. Lung Cancer 35, 155-163.
42. Uchida T, Minei S, Gao J-P, Wang C, Satoh T, and Baba S (2002). Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. Oncol Rep 9, 253-259.
43. Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, et al. (2010). High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 10, 186.
44. Jorgensen TN, McKee A, Wang M, Kushnir E, White J, Refaeli Y, Kappler JW, and Marrack P (2007). Bim and Bcl-2 mutually affect the expression of the other in T cells. J Immunol 179, 3417-3424.
45. Zhan Q, Kontny U, Iglesias M, Alamo I Jr, Yu K, Hollander MC, Woodworth CD, and Fornace AJ Jr (1999). Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress. Oncogene 18, 297-304.
46. Bourgarel-Rey V, Savry A, Hua G, Carré M, Bressin C, Chacon C, Imbert J, Braguer D, and Barra Y (2009). Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter. Biochem Pharmacol 78, 1148-1156.
47. Maiyar AC, Huang AJ, Phu PT, Cha HH, and Firestone GL (1996). p53 stimulates promoter activity of the sgk serum/glucocorticoid-inducible serine/threonine protein kinase gene in rodent mammary epithelial cells. J Biol Chem 271, 12414-12422.
48. You H, Jang Y, You-Ten AI, Okada H, Liepa J, Wakeham A, Zaugg K, and Mak TW (2004). p53-dependent inhibition of FKHRL1 in response to DNA damage through protein kinase SGK1. Proc Natl Acad Sci USA 101, 14057-14062.
49. Obexer P, Geiger K, Ambros PF, Meister B, and Ausserlechner MJ (2007). FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ 14, 534-547.
50. Young KW, Piñón LGP, Dhiraj D, Twiddy D, Macfarlane M, Hickman J, and Nicotera P (2010). Mitochondrial fragmentation and neuronal cell death in response to the Bcl-2/Bcl-x(L)/Bcl-w antagonist ABT-737. Neuropharmacology 58, 1258-1267.
51. Shroff EH, Snyder CM, Budinger GRS, Jain M, Chew T-L, Khuon S, Perlman H, and Chandel NS (2009). BH3 peptides induce mitochondrial fission and cell death independent of BAX/BAK. PLoS One 4, e5646.
52. Thomas KJ and Jacobson MR (2012). Defects in mitochondrial fission protein dynamin-related protein 1 are linked to apoptotic resistance and autophagy in a lung cancer model. PLoS One 7, e45319.
53. Nordigården A, Kraft M, Eliasson P, Labi V, Lam EW-F, Villunger A, and Jönsson JI (2009). BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Blood 113, 2302-2311.
54. CraggMS, Kuroda J, PuthalakathH, HuangDCS, and Strasser A (2007). Gefitinibinduced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4, 1681-1689; discussion 1690.
55. Patel MP, Masood A, Patel PS, and Chanan-Khan AA (2009). Targeting the Bcl-2. Curr Opin Oncol 21, 516-523.
56. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, et al. (2012). Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA 109, 2766-2771.
57. Sakakibara-Konishi J, Oizumi S, Kikuchi J, Kikuchi E, Mizugaki H, Kinoshita I, Dosaka-Akita H, and Nishimura M (2012). Expression of bim, noxa, and puma in non-small cell lung cancer. BMC Cancer 12, 286.